Advances in Gene Therapy for Sickle Cell Disease: From Preclinical Innovations to Clinical Implementation and Access...

Area of Science:

• Genetics
• Hematology
• Biotechnology

Background:

• Sickle cell disease (SCD) is an inherited blood disorder caused by a mutation in the beta-globin gene, leading to abnormal hemoglobin S.
• SCD causes red blood cell deformation, vaso-occlusion, pain, anemia, organ damage, and increased risk of stroke.
• Current treatments like gene therapy and stem cell transplants have limited accessibility.

Purpose of the Study:

• To review recent advancements in gene and cell therapies for sickle cell disease.
• To highlight the progress of FDA-approved treatments, including Lyfgenia and Casgevy.
• To examine the challenges and future directions of gene therapy for SCD.

Main Methods:

• Review of preclinical studies and clinical trials in gene and cell therapy for SCD.
• Focus on gene editing techniques such as CRISPR, base editing, and prime editing.
• Analysis of FDA-approved therapies and their accessibility.

Main Results:

• Autologous gene therapy is emerging as a potential curative option for SCD.
• Gene editing technologies show promise in correcting the causative mutation for SCD.
• FDA-approved treatments like Lyfgenia and Casgevy represent significant progress.

Conclusions:

• Gene therapy holds significant promise for curing sickle cell disease.
• Ongoing challenges related to accessibility, safety, and long-term efficacy need to be addressed.
• Continued research and development are crucial for the future of SCD gene therapy.